51. Using antibody directed phototherapy to target oesophageal adenocarcinoma with heterogeneous HER2 expression
- Author
-
Dahmane Oukrif, Michael Gandy, Mahendra Deonarain, Rehan Haidry, Marco Novelli, Manuel Rodriguez-Justo, Halla W. Reinert, Rifat Hamoudi, Laura Funnell, I Puccio, Saif Khan, Savvas Saouros, Vinay Sehgal, Ioanna Stamati, Jared S Marklew, Gokhan Yahioglu, Hayley Pye, Mohammed A. Butt, Laurence Lovat, Hayley C. Whitaker, and Maryam Qurashi
- Subjects
0301 basic medicine ,Antibody-drug conjugate ,medicine.medical_treatment ,Photodynamic therapy ,03 medical and health sciences ,0302 clinical medicine ,Pharmacokinetics ,In vivo ,HER2 ,medicine ,Cytotoxicity ,biology ,business.industry ,medicine.disease ,In vitro ,030104 developmental biology ,Oncology ,photodynamic therapy ,Dysplasia ,030220 oncology & carcinogenesis ,biology.protein ,Cancer research ,oesophageal adenocarcinoma ,antibody drug conjugate ,Antibody ,heterogeneity ,business ,Research Paper - Abstract
Early oesophageal adenocarcinoma (OA) and pre-neoplastic dysplasia may be treated with endoscopic resection and ablative techniques such as photodynamic therapy (PDT). Though effective, discrete areas of disease may be missed leading to recurrence. PDT further suffers from the side effects of off-target photosensitivity. A tumour specific and light targeted therapeutic agent with optimised pharmacokinetics could be used to destroy residual cancerous cells left behind after resection. A small molecule antibody-photosensitizer conjugate was developed targeting human epidermal growth factor receptor 2 (HER2). This was tested in an in vivo mouse model of human OA using a xenograft flank model with clinically relevant low level HER2 expression and heterogeneity. In vitro we demonstrate selective binding of the conjugate to tumour versus normal tissue. Light dependent cytotoxicity of the phototherapy agent in vitro was observed. In an in vivo OA mouse xenograft model the phototherapy agent had desirable pharmacokinetic properties for tumour uptake and blood clearance time. PDT treatment caused tumour growth arrest in all the tumours despite the tumours having a clinically defined low/negative HER2 expression level. This new phototherapy agent shows therapeutic potential for treatment of both HER2 positive and borderline/negative OA.
- Published
- 2018